Expert: FDA guidance for Alzheimer's drugs should help industry

02/9/2013 | Columbus Dispatch (Ohio), The

New draft guidance for the development of drugs targeting the early stages of Alzheimer's disease will assist drugmakers with the design of clinical trials aimed at detecting disease before the onset of dementia, said Dr. Paul Aisen, director of the Alzheimer's Disease Cooperative Study. "I think this will be hugely useful to the pharmaceutical industry," he said.

View Full Article in:

Columbus Dispatch (Ohio), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ